Obesity In India

With cheaper GLP-1 pills entering India, access could improve significantly, but experts warn that affordability must be balanced with strong regulation and patient safety

Global drugmakers are prioritising China and Japan for GLP-1 investments due to stronger pricing power and adoption, while India remains a large but price-sensitive market with slower premium uptake

Regulators have been asked to track adverse events as India tightens oversight on popular obesity drugs amid rising demand and concerns over misuse and misleading promotions

India is the first major country after Canada where Novo is losing patent on semaglutide and will see an onslaught of generic versions

A new global report places India second worldwide for children living with overweight and obesity and warns that rising BMI levels could trigger early hypertension, heart diseases

A major Lancet study finds adults with obesity are far more likely to be hospitalised or die from infections, linking nearly one in 10 infection deaths worldwide to excess weight

A nationwide LocalCircles survey shows obesity is no longer an individual issue, with most Indians reporting obese family members or friends, underscoring India's growing public health challenge

Economic Survey 2025-26 flags rising obesity and ultra-processed food intake as risks to productivity, healthcare spending and public finances, calling for policy action beyond consumer awareness

Endocrinologist explains how to build a realistic weight-loss plan that can help you lose fat without regaining it

Changing lifestyles, nutritional gaps and untreated mental health issues are pushing chronic diseases into younger age groups across India

New research shows people regain weight far faster after stopping obesity drugs than after dieting, with benefits fading quickly and raising questions about how long GLP-1 medicines need to be taken

Eating eggs has been repeatedly shown to help people feel fuller for longer and eat less at later meals, including among people who are overweight or obese

India still has a critical advantage: ultra-processed foods account for a very small share of current diets

Novo's strategy emphasises price cuts and accelerated launches, while Lilly's products benefitted from hitting the market early

Why does belly fat creep up after 30 even if nothing has changed? A California-based gastroenterologist trained at AIIMS explains the science behind it and what can help reverse it

Entry of generics post March 2026, patient dropouts to affect sales values, say experts

From regulating appetite to improving blood sugar control, GLP-1 drugs like Ozempic are emerging as powerful metabolic tools at a time when India urgently needs better solutions

Mounjaro is part of a new generation of weight-loss and diabetes drugs that target metabolic hormones. Introduced in March, it was launched ahead of rival Novo Nordisk's Wegovy

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's Mounjaro in India

Unlike injectable Mounjaro, which focuses on patients with a BMI above 35, Orforglipron is designed for the larger group of patients with a BMI of 27-34, offering an expected weight reduction of 12-16